The kinase inhibitor crizotinib, which has been shown to negatively affect proliferation of cells expressing ROS1 fusions [14], has demonstrated clinical efficacy in ROS1 fusion positive NSCLC and IMT patients [15; Ou SI, et al. Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC), WCLC 2013 Meeting, 2013]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.